Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2)

Request For Quotation
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) manufacturers

  • PC407-ws
  • PC407-ws pictures
  • $1520.00
  • 2026-05-11
  • CAS:1242169-24-9
  • Purity:
  • Supply Ability: 10g
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) Basic information
Product Name:Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2)
Synonyms:Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2);PC407 ws;PC407ws;PC407-ws;PC407 ws,PC-407-ws
CAS:1242169-24-9
MF:C24H19F3N3NaO5S
MW:541.48
EINECS:
Product Categories:
Mol File:1242169-24-9.mol
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) Structure
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) Chemical Properties
Safety Information
MSDS Information
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) Usage And Synthesis
DescriptionPC407-ws is a water-soluble novel potential COX-2 inhibitor.
UsesCOX-2-IN-50 is a water-soluble COX-2 inhibitor with significant analgesic activity. The solubility of COX-2-IN-50 in water reaches 20.3 mg/mL, far exceeding the 1.6 μg/mL of its precursor compound PC407. COX-2-IN-50 demonstrates good biocompatibility and is suitable for the development of injectable dosage forms. COX-2-IN-50 has proven its analgesic effect in vivo and shows potential application value[1].
References[1] Enhanced water-soluble derivative of PC407 as a novel potential COX-2 inhibitor injectable formulation
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) Preparation Products And Raw materials
Tag:Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2)(1242169-24-9) Related Product Information
Gallic acid GYY 4137 Morpholine salt Cianidanol L-Epicatechin Carprofen Acetaminophen